Compare TransMedics Group Inc (TMDX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Verisign, Inc. — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while Verisign, Inc. trades at $303.74 (market cap $26.92B). The key difference: Verisign, Inc. is far larger — about 9.8× TransMedics Group Inc's market cap, and Verisign, Inc. pays a 1.09% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Verisign, Inc. for 123 Days on average.
| TMDX | VRSN | |
|---|---|---|
Market Cap | $2.74B | $26.92B |
Volume | 949,331 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $150.42 | $310.00 |
52-Week Low | $61.99 | $211.49 |
Typical Hold Time | 24 Days | 123 Days |
Enterprise Value | $3.13B | $28.23B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
VeriSign (VRSN) trades at $297.79, up 1.21% today, with a bullish technical signal and strong fundamentals including a 49.77% net income margin. Recent earnings show mixed quarterly beats, while institutional buying and a pending Q3 2026 report highlight investor interest. The stock faces resistance near $299, with support at $296.
Outlook remains positive with a consensus price target of $348, driven by robust cash flow and domain growth, though risks include an antitrust lawsuit and high valuation multiples. The buy-rated stock offers upside potential but requires monitoring of legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
